ProUroCare Medical Inc. (PUMD) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerProUroCare Medical Inc. (PUMD) trades at $0.0001. ProUroCare Medical Inc. focuses on developing products for detecting and characterizing male urological prostate disease. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for PUMD: PUMD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
ProUroCare Medical Inc. (PUMD) Healthcare & Pipeline Overview
ProUroCare Medical Inc., founded in 1999, operates within the medical devices sector, focusing on the development of the ProUroScan System for prostate imaging. The company aims to improve the detection and characterization of male urological prostate diseases, primarily through its agreements with Artann Laboratories Inc.
What Is the Investment Thesis for PUMD?
ProUroCare Medical Inc. presents a highly speculative investment opportunity, given its small market capitalization of $0.00B and the inherent risks associated with OTC-listed companies. The company's sole product, the ProUroScan System, targets the prostate disease detection market, but its commercial success is uncertain. Key value drivers hinge on the successful commercialization and adoption of the ProUroScan System by urologists. Growth catalysts include potential regulatory approvals and expanded licensing agreements. However, the company's high beta of 18.51 indicates extreme volatility, and the absence of dividends reflects its current financial state. Investors should carefully consider the risks associated with investing in a micro-cap OTC stock with limited financial resources.
Based on FMP financials and quantitative analysis
PUMD Key Highlights
Market capitalization of $0.00B, indicating a micro-cap company with high growth potential but also significant risk.
- Free cash flow of $0.00B, reflecting the company's current stage of development and reliance on external funding.
- Beta of 18.51, signifying extremely high volatility compared to the overall market.
- No dividend yield, consistent with a growth-oriented company reinvesting earnings.
- Focus on the ProUroScan System, a prostate imaging technology, indicating a niche market focus.
Who Are PUMD's Competitors?
PUMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $0.84 | -1.12% | 30 5-pillar | |
| NVNO enVVeno Medical Corporation | $8.10 | +0.75% | $5.63M | 30 5-pillar |
| BDMD Baird Medical Investment Holdings Limited | $0.75 | +0.91% | $31.7M | — |
| SNWV SANUWAVE Health, Inc. | $4.82 | +4.33% | $41.5M | 36 5-pillar |
| SRTS Sensus Healthcare, Inc. | $2.98 | +1.02% | $49.1M | 31 5-pillar |
| HYPD Hyperion DeFi, Inc. | $3.73 | +1.91% | $56.5M | 36 5-pillar |
| LNSR LENSAR, Inc. | $6.75 | +2.74% | $82.9M | 45 5-pillar |
| APYX Apyx Medical Corporation | $2.55 | +2.00% | $107M | 33 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PUMD's Key Strengths?
Specialized focus on prostate disease detection.
- Proprietary ProUroScan System technology.
- Licensing agreements with Artann Laboratories Inc.
What Are PUMD's Weaknesses?
Limited financial resources.
- Small market capitalization.
- Dependence on a single product (ProUroScan System).
- OTC listing indicates higher risk.
What Are the Key Risks for PUMD?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established medical device companies with greater resources.
- Technological obsolescence of the ProUroScan System.
- Regulatory hurdles and delays in obtaining approvals.
- Limited financial resources and dependence on external funding.
- High volatility and illiquidity due to OTC listing.
What Are PUMD's Competitive Advantages?
- Proprietary ProUroScan System technology.
- Licensing, development, and commercialization agreements with Artann Laboratories Inc.
- Focus on a niche market within prostate disease detection.
What Does PUMD Do?
ProUroCare Medical Inc., established in 1999, is dedicated to the development of innovative solutions for the detection and characterization of male urological prostate diseases. The company's core product is the ProUroScan System, an advanced prostate imaging system designed to assist physicians in identifying and documenting abnormalities in the prostate that have been initially detected through a digital rectal exam. This technology aims to provide a more detailed and accurate assessment of prostate health, potentially leading to earlier and more effective interventions. ProUroCare's business model centers around the licensing, development, and commercialization of its ProUroScan System. A key aspect of its strategy involves collaborative agreements with Artann Laboratories Inc., which likely contributes to the development and distribution of the ProUroScan System. The company's focus remains on enhancing the diagnostic capabilities for prostate diseases, addressing a significant need in men's healthcare. Based in Eden Prairie, Minnesota, ProUroCare Medical Inc. continues to navigate the medical device landscape with its specialized technology.
What Products and Services Does PUMD Offer?
- Develop products for the detection of male urological prostate disease.
- Develop products for the characterization of male urological prostate disease.
- Offer the ProUroScan System, a prostate imaging system.
- Aid physicians in documenting abnormalities in the prostate.
- Utilize digital rectal exams to detect abnormalities.
- Engage in licensing agreements for the ProUroScan System.
- Engage in development agreements for the ProUroScan System.
- Engage in commercialization agreements for the ProUroScan System.
How Does PUMD Make Money?
- Develop and commercialize the ProUroScan System for prostate imaging.
- Generate revenue through licensing, development, and commercialization agreements.
- Collaborate with Artann Laboratories Inc. for product development and distribution.
What Industry Does PUMD Operate In?
ProUroCare Medical Inc. operates within the medical device industry, specifically targeting the market for prostate disease detection and characterization. This market is driven by the increasing prevalence of prostate cancer and other urological conditions, as well as advancements in diagnostic technologies. The competitive landscape includes established medical device companies and specialized firms offering various prostate imaging and diagnostic solutions. ProUroCare's ProUroScan System aims to differentiate itself by providing a more detailed assessment of prostate abnormalities detected during digital rectal exams.
Who Are PUMD's Key Customers?
- Urologists
- Medical facilities
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
ProUroCare Medical Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Eden Prairie, US. The company is led by CEO Benjamin Banks. PUMD has traded publicly since 2022.
Key Financial Metrics
Return on equity for ProUroCare Medical Inc. stands at 90.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
ProUroCare Medical Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Insider Activity
12 transactions · 5 purchases, 0 sales, 7 other transactions · 4 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
PUMD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
PUMD Latest News
No recent news available for PUMD.
PUMD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PUMD.
Price Targets
Wall Street price target analysis for PUMD.
PUMD MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PUMD; grades run from A+ (80-100) to F (below 30).
PUMD OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ProUroCare Medical Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial reporting, making it difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited or no financial reporting, making it difficult to assess the company's financial health.
- Low trading volume and liquidity, leading to wide bid-ask spreads and potential price volatility.
- Higher risk of fraud or manipulation due to the lack of regulatory oversight.
- Potential for delisting or suspension of trading.
- Limited access to capital and funding opportunities.
- Verify the company's registration and legal status.
- Attempt to locate and review any available financial statements or disclosures.
- Assess the company's management team and their experience.
- Research the company's products or services and their market potential.
- Evaluate the company's competitive landscape and its ability to compete.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before investing.
- Company has been in operation since 1999.
- Focus on developing a specific medical device (ProUroScan System).
- Has licensing, development, and commercialization agreements with Artann Laboratories Inc.
PUMD Healthcare Stock FAQ
What do analysts say about PUMD stock?
As of 2026-03-16, there is no available analyst coverage or consensus for ProUroCare Medical Inc. (PUMD) due to its OTC listing and small market capitalization. Investors should conduct their own thorough research and due diligence before considering an investment in PUMD.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on publicly available sources and may be limited due to the company's OTC listing.
- Financial data is based on the provided information and may not be comprehensive.